Residency · Residency · Respirology

Lung Cancer - Screening, Staging, and Multidisciplinary Management

Epidemiology

Global Burden

Lung cancer remains the leading cause of cancer death worldwide, responsible for approximately 1.8 million deaths annually. The overall 5-year survival rate is approximately 22%, a figure that has been steadily improving due to advances in targeted therapies, immunotherapy, and screening programs enabling earlier diagnosis. Non-small cell lung cancer (NSCLC) accounts for 85% of cases, with adenocarcinoma being the most common histologic subtype followed by squamous cell carcinoma and large cell carcinoma, while small cell lung cancer (SCLC) comprises the remaining 15%. The incidence of lung cancer is declining in many countries as a result of smoking reduction campaigns, though an increasing proportion of cases is occurring in never-smokers, particularly among Asian women with adenocarcinoma.

Screening

LDCT Screening

The evidence base for lung cancer screening with low-dose computed tomography (LDCT) was established by two landmark trials. The National Lung Screening Trial (NLST), published in 2011, compared LDCT to chest radiography in a high-risk population aged 55-74 with 30 or more pack-years of smoking history who were current smokers or had quit within 15 years, and demonstrated a 20% relative reduction in lung cancer mortality with a 6.7% absolute reduction. The NELSON trial, published in 2020, compared LDCT to no screening in men aged 50-74 with substantial smoking histories and demonstrated a 24% lung cancer mortality reduction in men and 33% in women, while introducing volume-based nodule assessment as a superior method for evaluating screening-detected nodules. The USPSTF 2021 criteria expanded screening eligibility to annual LDCT for adults aged 50-80 with a 20 or more pack-year smoking history who are currently smoking or quit within the past 15 years. This expansion from the previous criteria of age 55-80 with 30 or more pack-years broadens eligibility in a way that especially benefits Black individuals and women, who develop lung cancer at lower cumulative smoking exposures.

Screening Implementation

The positive screening rate is approximately 25%, with the majority representing false positives, and fewer than 5% of those screened are ultimately diagnosed with cancer. The Lung-RADS reporting system standardizes nodule classification into categories 1-4 based on size, density, and growth characteristics. Lung-RADS 1-2 designates negative or benign findings warranting continued annual screening. Lung-RADS 3 indicates a probably benign finding requiring 6-month follow-up CT. Lung-RADS 4A and 4B represent suspicious findings prompting 3-month CT or tissue sampling. Smoking cessation counseling must accompany screening, as LDCT alone is insufficient as a comprehensive lung cancer prevention strategy. Recognized harms of screening include false positives generating anxiety and potentially invasive procedures, overdiagnosis estimated at approximately 18%, cumulative radiation exposure, and incidental findings.

<image>A comprehensive lung cancer screening protocol flowchart based on USPSTF 2021 and Lung-RADS. Start with eligibility criteria (age 50-80, >= 20 pack-years, current/former smoker quit < 15 years). Show annual LDCT with Lung-RADS categorization. For each Lung-RADS category (1 through 4X), show the recommended follow-up: 1-2 (continue annual screening), 3 (6-month CT), 4A (3-month CT or PET/CT), 4B (chest CT with/without contrast, PET/CT, and/or tissue sampling), 4X (additional features increasing suspicion). Include a branch for incidental findings. Show nodule size thresholds for solid (>= 6 mm suspicious) and subsolid (>= 6 mm ground glass, >= 6 mm part-solid) nodules. Include a sidebar showing shared decision-making elements and smoking cessation integration.</image>

Diagnosis and Staging

Tissue Acquisition

Multiple modalities are available for obtaining tissue diagnosis. Bronchoscopy with EBUS-TBNA is the preferred approach for central lesions and for mediastinal and hilar lymph node staging, achieving a diagnostic yield exceeding 90% for lymph node sampling. CT-guided transthoracic needle biopsy is the standard approach for peripheral lesions, with a diagnostic yield of 85-95% and a pneumothorax rate of 15-25%, of which approximately 5% require chest tube placement. Navigational bronchoscopy, including electromagnetic navigation and robotic platforms, provides access to peripheral nodules not reachable by conventional bronchoscopy, with a diagnostic yield of 60-80% that is improving with newer platforms. Robotic-assisted bronchoscopy systems, including the Monarch and Ion platforms, offer improved reach to peripheral lesions and are experiencing growing clinical adoption. EBUS-TBNA has replaced mediastinoscopy as the first-line technique for mediastinal staging, with a sensitivity of 89% and specificity approaching 100%.

Molecular Testing

All patients with advanced NSCLC, particularly non-squamous histology, should undergo comprehensive molecular profiling before treatment initiation. The minimum panel includes EGFR mutations, ALK rearrangement, ROS1 rearrangement, BRAF V600E, KRAS G12C, NTRK fusions, MET exon 14 skipping, RET rearrangement, and HER2 mutations. PD-L1 expression assessed by tumor proportion score (TPS) guides immunotherapy decisions. Next-generation sequencing (NGS) panels are preferred over sequential single-gene testing as they are faster and tissue-sparing. Liquid biopsy through circulating tumor DNA (ctDNA) analysis is available for patients unable to undergo tissue biopsy or for identifying resistance mechanisms, with FDA approval for EGFR mutations and sensitivity of approximately 70-80% in advanced disease.

TNM Staging (8th Edition)

The 8th edition TNM staging system classifies tumors by size and local invasion: T1 encompasses tumors up to 3 cm, T2 tumors of 3-5 cm, T3 tumors of 5-7 cm, and T4 tumors exceeding 7 cm or invading the mediastinum, diaphragm, heart, or great vessels. Nodal staging designates N0 for no nodal involvement, N1 for ipsilateral hilar nodes, N2 for ipsilateral mediastinal nodes, and N3 for contralateral mediastinal, supraclavicular, or scalene nodes. Metastatic staging distinguishes M1a (contralateral lung, pleural or pericardial effusion), M1b (single extrathoracic metastasis), and M1c (multiple extrathoracic metastases).

Staging Workup

The staging workup includes CT of the chest and abdomen with contrast, PET-CT for staging and detection of occult metastases (with awareness of false positives in inflammatory conditions and false negatives in lesions below 8 mm, ground glass opacity-predominant adenocarcinoma, and carcinoid tumors), brain MRI for all Stage II-IV NSCLC and all SCLC, and invasive mediastinal staging with EBUS-TBNA with or without mediastinoscopy for clinically N0 or N1 patients with PET-positive mediastinum or planned surgical resection.

Treatment by Stage - NSCLC

Early Stage (I-II)

Surgical resection remains the cornerstone of early-stage NSCLC management. Lobectomy is the standard procedure, though sublobar resection with segmentectomy is now acceptable for peripheral T1a-T1b N0 tumors of 2 cm or less, as the JCOG0802 and CALGB 140503 trials demonstrated non-inferiority for these small tumors. Stereotactic body radiation therapy (SBRT) achieves local control rates exceeding 90% at 3 years for medically inoperable early-stage disease. Adjuvant cisplatin-based doublet chemotherapy is recommended for Stage II and resected Stage IIIA disease, with the LACE meta-analysis demonstrating a 5.4% absolute survival benefit. The ADAURA trial established adjuvant osimertinib for 3 years in resected Stage IB-IIIA EGFR-mutant NSCLC, with 5-year overall survival of 88% versus 78%, representing a significant survival benefit reported in 2023. Adjuvant atezolizumab, validated in IMpower010, provides disease-free survival benefit for resected Stage II-IIIA disease with PD-L1 expression of 1% or greater. Neoadjuvant immunotherapy combined with chemotherapy was established as practice-changing by CheckMate 816, which demonstrated that nivolumab plus chemotherapy for 3 cycles before surgery in resectable Stage IB-IIIA disease achieved a pathological complete response rate of 24% versus 2.2%, with significant event-free survival benefit.

Locally Advanced (Stage III)

Unresectable Stage III NSCLC is treated with concurrent chemoradiation (cisplatin plus etoposide or carboplatin plus paclitaxel with 60 Gy radiation) followed by durvalumab for 12 months, as established by the PACIFIC trial, which demonstrated a 5-year overall survival of 42.9% versus 33.4% and fundamentally changed the standard of care. Potentially resectable Stage IIIA disease is managed with a multimodality approach incorporating neoadjuvant chemoimmunotherapy followed by surgery and adjuvant immunotherapy.

Metastatic (Stage IV) - Without Driver Mutations

Treatment stratification is guided by PD-L1 expression. For PD-L1 of 50% or greater, pembrolizumab monotherapy (KEYNOTE-024) or pembrolizumab plus chemotherapy (KEYNOTE-189) is appropriate. For PD-L1 of 1-49%, pembrolizumab plus chemotherapy is recommended based on KEYNOTE-189, which demonstrated a median overall survival of 22 months versus 10.6 months. For PD-L1 below 1%, chemotherapy plus immunotherapy is used, with evidence from KEYNOTE-189, CheckMate 9LA, and IMpower150. CheckMate 227 demonstrated that nivolumab plus ipilimumab is an alternative first-line option for PD-L1 of 1% or greater, independent of tumor mutational burden.

Metastatic - With Driver Mutations

Targeted therapies have transformed outcomes for patients with actionable driver mutations. For EGFR-mutant NSCLC, osimertinib is the first-line standard based on the FLAURA trial (38.6 months OS versus 31.8), with the FLAURA2 trial demonstrating even better PFS with osimertinib plus chemotherapy. Amivantamab plus lazertinib is available for EGFR exon 20 insertions (PAPILLON). For ALK-rearranged disease, alectinib is first-line per the ALEX trial (34.8 months PFS), with lorlatinib offering even longer PFS per the CROWN trial. ROS1 rearrangements are treated with crizotinib or entrectinib. KRAS G12C mutations are targeted by sotorasib (CodeBreaK 100) or adagrasib (KRYSTAL-1). BRAF V600E is treated with dabrafenib plus trametinib. MET exon 14 skipping mutations are targeted by capmatinib or tepotinib. RET rearrangements respond to selpercatinib or pralsetinib. NTRK fusions are treated with larotrectinib or entrectinib.

Small Cell Lung Cancer (SCLC)

Staging and Treatment

Limited-stage SCLC, confined to one hemithorax and regional lymph nodes within a single radiation port, is treated with concurrent chemoradiation using cisplatin plus etoposide with thoracic radiation therapy (45 Gy twice daily or 60-66 Gy daily). Prophylactic cranial irradiation (PCI), administered to patients who demonstrate a treatment response, reduces brain metastasis risk and provides a modest overall survival benefit. Extensive-stage SCLC is treated with first-line carboplatin plus etoposide plus atezolizumab, as established by IMpower133 (12.3 months OS versus 10.3 months, representing the first overall survival improvement in extensive-stage SCLC in decades), or carboplatin plus etoposide plus durvalumab per the CASPIAN trial. PCI in extensive-stage disease remains debated and may be replaced by MRI surveillance as suggested by the Japanese JCOG0601 trial. Thoracic radiation therapy consolidation after chemotherapy may improve overall survival in select patients as shown in the CREST trial. Recurrent SCLC is treated with topotecan, lurbinectedin (FDA approved), and emerging DLL3-targeted agents including tarlatamab, a BiTE antibody evaluated in the DeLLphi-301 trial.

<image>A treatment decision algorithm for newly diagnosed lung cancer. Start with histologic diagnosis (NSCLC vs. SCLC). For NSCLC: determine stage (I-II, III, IV). Stage I-II: surgery (lobectomy/segmentectomy) +/- adjuvant therapy (molecular-guided: osimertinib if EGFR+, atezolizumab if PD-L1+); or neoadjuvant chemoimmunotherapy (CheckMate 816). Stage III unresectable: concurrent chemoRT then durvalumab (PACIFIC). Stage IV: branch by molecular testing results - if driver mutation (EGFR/ALK/ROS1/BRAF/KRAS/MET/RET/NTRK): targeted therapy first-line; if no driver: stratify by PD-L1 (>= 50%: pembrolizumab +/- chemo; 1-49%: chemo + pembrolizumab; < 1%: chemo + IO). For SCLC: limited stage (chemoRT + PCI) vs. extensive stage (chemo + atezolizumab/durvalumab). Include molecular testing panel list and biopsy method selection. Use color-coded pathways for surgery (green), radiation (blue), systemic therapy (orange), targeted therapy (purple).</image>

Multidisciplinary Tumor Board

All lung cancer patients should be discussed at a multidisciplinary tumor board. The team includes a pulmonologist, thoracic surgeon, medical oncologist, radiation oncologist, pathologist, radiologist, nurse specialist, and palliative care representative. MDT discussion improves staging accuracy, treatment appropriateness, and survival outcomes.

Key Clinical Pearls

• USPSTF 2021 expanded LDCT screening eligibility to age 50+ with >= 20 pack-years; this especially benefits Black individuals who develop lung cancer at lower pack-year exposures
• All advanced NSCLC should undergo comprehensive molecular profiling (NGS panel) before treatment initiation; targeted therapies have dramatically improved survival for driver mutation-positive cancers
• The PACIFIC regimen (concurrent chemoradiation followed by durvalumab) is the standard of care for unresectable stage III NSCLC with 5-year OS > 40%
• Neoadjuvant nivolumab + chemotherapy (CheckMate 816) is practice-changing for resectable stage IB-IIIA, achieving pathological complete response in 24% of patients
• Immunotherapy is ineffective and potentially harmful in EGFR/ALK-positive NSCLC; always test for driver mutations before starting immunotherapy

References

1. National Lung Screening Trial Research Group. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N Engl J Med. 2011;365(5):395-409. (NLST)
2. Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973-1985. (CheckMate 816)
3. Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350. (PACIFIC)
4. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113-125. (FLAURA)
5. Horn L, Mansfield AS, Szczesna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379(23):2220-2229. (IMpower133)

Read this lecture as Markdown